The DOI matches its Crossref record.
How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?
Open accessAbstract
OBJECTIVE: Angiotensin II (AII) and aldosterone are not always fully suppressed during chronic angiotensin converting enzyme (ACE) inhibitor treatment. In congestive heart failure (CHF) such failure of hormonal suppression is associated with increased mortality. This study examined how common AII and aldosterone increases are observed during routine clinical practice. PATIENTS AND METHODS: 91 patients with symptomatic (mean New York Heart Association class 2.7) CHF (mean (SD) left ventricular ejection fraction 29.9 (8)%, range 9–46%) were studied 4–6 hours after ACE inhibitor dosing. A representative range of ACE inhibitors (enalapril, lisinopril, captopril, perindopril, and fosinopril) was examined. RESULTS: Supine measurements showed a wide range of AII (10.5 (25.5) pg/ml), aldosterone (130.8 (136) pg/ml), and serum ACE (12.1 (13.3) EU/l; excludes captopril data) concentrations on diuretics. AII concentrations > 10 pg/ml were seen in 15% of patients, and aldosterone concentrations > 144 pg/ml were seen in 38% of patients. AII concentrations were significantly correlated (p < 0.001) with ACE but not with aldosterone concentrations. Aldosterone concentrations were not significantly correlated with ACE concentrations. CONCLUSIONS: AII “reactivation” occurred in 15% and failure of aldosterone suppression in 38% of routine CHF patients taking ACE inhibitor treatment. AII “reactivation” was associated with both low and high levels of ACE activity, which suggests that multiple different mechanisms are at play. In patients with high plasma ACE concentrations, non-compliance should be considered along with inadequate dose titration. In patients with low plasma ACE and high AII concentrations, non-ACE mediated production of AII may be operative. Raised aldosterone concentrations appear to be more common than AII “reactivation”. It is important to establish the cause of detectable or increased AII concentrations in a heart failure patient treated with an ACE inhibitor. The measurement of serum ACE may help to identify the likely cause as poor compliance or inadequate dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The renin-angiotensin-aldosterone system and its suppression
Ames, M. K., Atkins, C. E., & Pitt, B. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15454 · Cited by 433
The incidence and implications of aldosterone breakthrough
Bomback, A. S., & Klemmer, P. J. (2007) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0575 · Cited by 420
Angiotensin II Induces Skeletal Muscle Atrophy by Activating TFEB-Mediated MuRF1 Expression
Du Bois, P., Pablo Tortola, C., Lodka, D., Kny, M., Schmidt, F., Song, K., Schmidt, S., Bassel-Duby, R., Olson, E. N., & Fielitz, J. (2015) · Circulation Research · doi:10.1161/circresaha.114.305393 · Cited by 92
Brown, J. M., Williams, J. S., Luther, J. M., Garg, R., Garza, A. E., Pojoga, L. H., Ruan, D. T., Williams, G. H., Adler, G. K., & Vaidya, A. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.01910 · Cited by 88
Brown, J., de Boer, I. H., Robinson-Cohen, C., Siscovick, D. S., Kestenbaum, B., Allison, M., & Vaidya, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3949 · Cited by 71
Metadata
- Authors
- MacFadyen, R. J., Lee, A. F. C., Morton, J. J., Pringle, S. D., & Struthers, A. D.
- Venue
- Heart
- Publisher
- BMJ
- Published
- 1999-07-01
- Volume
- 82
- Issue
- 1
- Pages
- 57-61
- ISSN
- 1355-6037 (ISSN-L)
- 1468-201X
- OpenAlex
- W2124737750
- Cited by
- 205
- References
- 0
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? https://app.cochat.ai/papers/10.1136/hrt.82.1.57
- The paper
- MacFadyen, R. J., Lee, A. F. C., Morton, J. J., Pringle, S. D., & Struthers, A. D. (1999). How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. https://doi.org/10.1136/hrt.82.1.57
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.